Elanco Animal Health (NASDAQ:ELAN) Director R David Hoover bought 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The shares were acquired at an average cost of $31.43 per share, with a total value of $628,600.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Elanco Animal Health stock opened at $30.64 on Friday. Elanco Animal Health has a 52 week low of $28.00 and a 52 week high of $37.61.

Elanco Animal Health (NASDAQ:ELAN) last released its earnings results on Wednesday, February 6th. The company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.03. The business had revenue of $799.30 million for the quarter, compared to analysts’ expectations of $804.07 million. The business’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.12 earnings per share.

Several institutional investors have recently added to or reduced their stakes in the company. American Century Companies Inc. lifted its stake in Elanco Animal Health by 142.5% during the fourth quarter. American Century Companies Inc. now owns 2,077,810 shares of the company’s stock worth $65,513,000 after purchasing an additional 1,220,878 shares during the last quarter. Geode Capital Management LLC bought a new position in Elanco Animal Health during the fourth quarter worth $18,592,000. Norges Bank bought a new position in Elanco Animal Health during the fourth quarter worth $60,526,000. FMR LLC lifted its stake in Elanco Animal Health by 34.5% during the fourth quarter. FMR LLC now owns 4,415,172 shares of the company’s stock worth $139,210,000 after purchasing an additional 1,131,504 shares during the last quarter. Finally, Penn Capital Management Co. Inc. lifted its stake in Elanco Animal Health by 35.9% during the fourth quarter. Penn Capital Management Co. Inc. now owns 46,748 shares of the company’s stock worth $4,268,000 after purchasing an additional 12,352 shares during the last quarter.

Several brokerages have issued reports on ELAN. Credit Suisse Group reaffirmed a “hold” rating and issued a $33.00 price objective on shares of Elanco Animal Health in a research report on Friday, January 4th. Zacks Investment Research raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research report on Monday, December 17th. Morgan Stanley began coverage on shares of Elanco Animal Health in a research report on Wednesday. They issued an “equal weight” rating and a $34.00 price objective for the company. Argus began coverage on shares of Elanco Animal Health in a research report on Tuesday, January 15th. They issued a “buy” rating and a $37.00 price objective for the company. Finally, BMO Capital Markets lowered their price objective on shares of Elanco Animal Health from $37.00 to $32.00 and set a “market perform” rating for the company in a research report on Wednesday, December 19th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $33.48.

ILLEGAL ACTIVITY WARNING: “Elanco Animal Health (ELAN) Director Acquires $628,600.00 in Stock” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2019/03/17/elanco-animal-health-elan-director-acquires-628600-00-in-stock.html.

Elanco Animal Health Company Profile

There is no company description available for Elanco Animal Health Inc

Read More: Leveraged Buyout (LBO) Explained

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.